Non-small Cell Lung Cancer Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
The component of a drug that produces the desired effects is known as the active pharmaceutical ingredient (API). Combination therapies, for example, in long term treatments have various active substances that cure different symptoms or act in different ways. API is the potent component in drug formulation and often used with additives or excipients to improve therapeutic efficacy of a medicine. Many pharmaceutial companies develop their API by own or by outsourcing operations. Some common examples of API are, diclofenac, propanolol, methotraxate etc.
MARKET SCOPE
The "Global Active Pharmaceutical Ingredient (API) Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the active pharmaceutical ingredient (API) market with detailed market segmentation by type of synthesis and therapeutic application. The report provides key statistics on the market status of the leading active pharmaceutical ingredient (API) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type of synthesis the market is bifurcated as, biotech and synthetic.
- Based on therapeutic application the market is segmented as, cardiology, oncology, CNS and neurology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology and others.
MARKET DYNAMICS
Drivers:
- Significant growth in pharmaceutical & biotechnology companies.
- Growth in R&D activities across the companies to develop novel molecules and APIs.
- Increasing prevalnece of chronic diseases, idiosyncratic diseases and advancements in API production activities.
Restraints:
- Issues such as higher manufacturing costs and time consuming method of API development.
- Unfavorable DPCO guidelines are also expected to restrain market growth.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Active pharmaceutical ingredient (API) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Active pharmaceutical ingredient (API) market in these regions.
IMPACT OF COVID-19 ON ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. But some of the API molecules such as, remdesivir, favipiravir, and other such API have shown promising outcomes against covid-19 infection which has impacted positively on API market growth however, COVID-19 has disrupted all the business and economic activities across the globe which is expected to have some impact on active pharmaceutical ingredient (API) market. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
![World Geography](https://www.theinsightpartners.com/assets/rdimages/world-geography.png)
Have a question?
![Analyst](https://www.theinsightpartners.com/assets/mrinal_kerhalkar.jpg)
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
![Analyst](https://www.theinsightpartners.com/assets/images/speak_analyst.gif)
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Active pharmaceutical ingredient (API) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Active pharmaceutical ingredient (API) market in these regions.
IMPACT OF COVID-19 ON ACTIVE PHARMACEUTICAL INGREDIENT (API) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. But some of the API molecules such as, remdesivir, favipiravir, and other such API have shown promising outcomes against covid-19 infection which has impacted positively on API market growth however, COVID-19 has disrupted all the business and economic activities across the globe which is expected to have some impact on active pharmaceutical ingredient (API) market. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Active pharmaceutical ingredient (API) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Active pharmaceutical ingredient (API) market are anticipated to lucrative growth opportunities in the future with the rising demand for Active pharmaceutical ingredient (API) in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Active pharmaceutical ingredient (API) market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Pfizer, Inc.
- Cipla Inc.
- Merck KGaA
- Bristol Myers Squibb
- GlaxoSmithKline plc
- Mylan N.V.
- Dr. Reddy's Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
This text is related
to segments covered.
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Non-small Cell Lung Cancer (NSCLC) Drugs Market - By Cancer Type
1.3.2 Non-small Cell Lung Cancer (NSCLC) Drugs Market - By Therapy
1.3.3 Non-small Cell Lung Cancer (NSCLC) Drugs Market - By Distribution Channel
1.3.4 Non-small Cell Lung Cancer (NSCLC) Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS - GLOBAL MARKET OVERVIEW
6.2. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - CANCER TYPE
7.1. OVERVIEW
7.2. CANCER TYPE MARKET FORECASTS AND ANALYSIS
7.3. ADENOCARCINOMA
7.3.1. Overview
7.3.2. Adenocarcinoma Market Forecast and Analysis
7.4. SQUAMOUS CELL CARCINOMA
7.4.1. Overview
7.4.2. Squamous Cell Carcinoma Market Forecast and Analysis
7.5. LARGE CELL CARCINOMA
7.5.1. Overview
7.5.2. Large Cell Carcinoma Market Forecast and Analysis
8. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPY
8.1. OVERVIEW
8.2. THERAPY MARKET FORECASTS AND ANALYSIS
8.3. BEVACIZUMAB
8.3.1. Overview
8.3.2. Bevacizumab Market Forecast and Analysis
8.4. DABRAFENIB/TRAMETINIB
8.4.1. Overview
8.4.2. Dabrafenib/Trametinib Market Forecast and Analysis
8.5. ERLOTINIB HYDROCHLORIDE
8.5.1. Overview
8.5.2. Erlotinib Hydrochloride Market Forecast and Analysis
8.6. OSIMERTINIB
8.6.1. Overview
8.6.2. Osimertinib Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Non-small Cell Lung Cancer (NSCLC) Drugs Market Overview
10.1.2 North America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis
10.1.3 North America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Cancer Type
10.1.4 North America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Therapy
10.1.5 North America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.1.6.1.1 United States Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.1.6.1.2 United States Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.1.6.1.3 United States Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.1.6.2 Canada Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.1.6.2.1 Canada Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.1.6.2.2 Canada Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.1.6.2.3 Canada Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.1.6.3 Mexico Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.1.6.3.1 Mexico Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.1.6.3.2 Mexico Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.1.6.3.3 Mexico Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market Overview
10.2.2 Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis
10.2.3 Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Cancer Type
10.2.4 Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Therapy
10.2.5 Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.2.6.1.1 Germany Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.2.6.1.2 Germany Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.2.6.1.3 Germany Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.2.6.2 France Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.2.6.2.1 France Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.2.6.2.2 France Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.2.6.2.3 France Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.2.6.3 Italy Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.2.6.3.1 Italy Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.2.6.3.2 Italy Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.2.6.3.3 Italy Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.2.6.4 Spain Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.2.6.4.1 Spain Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.2.6.4.2 Spain Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.2.6.4.3 Spain Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.2.6.5.1 United Kingdom Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.2.6.5.2 United Kingdom Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.2.6.5.3 United Kingdom Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.2.6.6.1 Rest of Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.2.6.6.2 Rest of Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.2.6.6.3 Rest of Europe Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market Overview
10.3.2 Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Cancer Type
10.3.4 Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Therapy
10.3.5 Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.3.6.1.1 Australia Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.3.6.1.2 Australia Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.3.6.1.3 Australia Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.3.6.2 China Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.3.6.2.1 China Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.3.6.2.2 China Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.3.6.2.3 China Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.3.6.3 Japan Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.3.6.3.1 Japan Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.3.6.3.2 Japan Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.3.6.3.3 Japan Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.3.6.4 Rest of Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.3.6.4.1 Rest of Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.3.6.4.2 Rest of Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.3.6.4.3 Rest of Asia-Pacific Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market Overview
10.4.2 Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Cancer Type
10.4.4 Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Therapy
10.4.5 Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.4.6.1.1 South Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.4.6.1.2 South Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.4.6.1.3 South Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.4.6.2.1 Saudi Arabia Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.4.6.2.2 Saudi Arabia Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.4.6.2.3 Saudi Arabia Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.4.6.3 U.A.E Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.4.6.3.1 U.A.E Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.4.6.3.2 U.A.E Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.4.6.3.3 U.A.E Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.4.6.4.2 Rest of Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.4.6.4.3 Rest of Middle East and Africa Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market Overview
10.5.2 South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis
10.5.3 South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Cancer Type
10.5.4 South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Therapy
10.5.5 South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.5.6.1.1 Brazil Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.5.6.1.2 Brazil Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.5.6.1.3 Brazil Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.5.6.2 Argentina Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.5.6.2.1 Argentina Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.5.6.2.2 Argentina Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.5.6.2.3 Argentina Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market
10.5.6.3.1 Rest of South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market by Cancer Type
10.5.6.3.2 Rest of South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market by Therapy
10.5.6.3.3 Rest of South and Central America Non-small Cell Lung Cancer (NSCLC) Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. NON-SMALL CELL LUNG CANCER (NSCLC) DRUGS MARKET, KEY COMPANY PROFILES
13.1. GLAXOSMITHKLINE PLC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. F. HOFFMANN-LA ROCHE LTD
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. NOVARTIS AG
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. ELI LILLY AND COMPANY
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ASTRAZENECA
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. PFIZER INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ONO PHARMACEUTICAL CO., LTD.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. MERCK SHARP AND DOHME CORP., (MERCK AND CO., INC.)
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. GlaxoSmithKline plc
2. F. Hoffmann-La Roche Ltd
3. Novartis AG
4. Eli Lilly And Company
5. AstraZeneca
6. Pfizer Inc.
7. Takeda Pharmaceutical Company Limited
8. ONO PHARMACEUTICAL CO., LTD.
9. Boehringer Ingelheim International GmbH
10. Merck Sharp & Dohme Corp., (Merck & Co., Inc.)
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.